ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Rethinking Premeds"
Episode Synopsis
Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!
Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158
Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470
We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158
Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470
We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust